Stay updated with breaking news from Barry Ticho. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Stoke Therapeutics (NASDAQ:STOK – Free Report) had its target price decreased by Cantor Fitzgerald from $18.00 to $14.00 in a research note released on Tuesday morning, Marketbeat.com reports. Cantor Fitzgerald currently has an overweight rating on the stock. Cantor Fitzgerald also issued estimates for Stoke Therapeutics’ FY2023 earnings at ($2.42) EPS and FY2024 earnings at […]
HC Wainwright reiterated their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK – Free Report) in a report released on Tuesday, Benzinga reports. They currently have a $35.00 price target on the stock. HC Wainwright also issued estimates for Stoke Therapeutics’ Q3 2023 earnings at ($0.63) EPS, FY2023 earnings at ($2.56) EPS, FY2024 earnings at […]
HC Wainwright restated their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK – Free Report) in a report issued on Tuesday, Benzinga reports. The firm currently has a $35.00 price target on the stock. HC Wainwright also issued estimates for Stoke Therapeutics’ Q3 2023 earnings at ($0.63) EPS, FY2023 earnings at ($2.56) EPS, FY2024 earnings […]
Stoke Therapeutics (NASDAQ:STOK – Get Free Report)‘s stock had its “outperform” rating reissued by investment analysts at Credit Suisse Group in a research report issued on Tuesday, Benzinga reports. They presently have a $23.00 target price on the stock. Credit Suisse Group’s price objective would indicate a potential upside of 294.51% from the company’s current […]
Stoke Therapeutics (NASDAQ:STOK – Get Free Report) announced its quarterly earnings results on Monday. The company reported ($0.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.06), MarketWatch Earnings reports. Stoke Therapeutics had a negative net margin of 679.83% and a negative return on equity of 47.86%. Stoke Therapeutics Stock […]